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Abstract
Aim To verify the safety and efficacy of
Ologen (OLO) implant as adjuvant compared
with low-dosage mitomycin-C (MMC) in
trabeculectomy.
Methods This was a prospective randomized
clinical trial with a 24-month follow-up. Forty
glaucoma patients (40 eyes) were assigned to
trabeculectomy with MMC or OLO. Primary
outcome includes target IOP at r21,r17, and
r15mmHg; complete (target IOP without
medications), and qualified success (target IOP
regardless of medications). Secondary
outcomes include bleb evaluation, according
to Moorfields Bleb Grading System (MBGS);
spectral domain optical coherence tomography
(SD-OCT) examination; number of glaucoma
medications; and frequency of postoperative
adjunctive procedures and complications.
Results The mean preoperative IOP was 26.5
(±5.2) in MMC and 27.3 (±6.0) in OLO eyes,
without statistical significance. One-day
postoperatively, the IOP dropped to 5.2 (±3.5)
and 9.2 (±5.5) mmHg, respectively (P¼ 0.009).
The IOP reduction was significant at end point
in all groups (P¼ 0.01), with a mean IOP of 16.0
(±2.9) and 16.5 (±2.1) mmHg in MMC and
OLO, respectively. The rates and Kaplan–Meier
curves did not differ for both complete and
qualified success at any target IOP. The bleb
height in OLO group was higher than MMC
one (Po0.05). SD-OCT analysis of successful/
unsuccessful bleb in patients with or without
complete success at IOP r17mmHg indicated
a sensitivity of 83% and 73% and a specificity of
75% and 67%, respectively, for MMC and OLO
groups. No adverse reaction to OLO was noted.
Conclusions Our results suggest that OLO
implant could be a new, safe, and effective
alternative to MMC, with similar long-term
success rate.
Eye (2011) 25, 1598–1606; doi:10.1038/eye.2011.219;
published online 16 September 2011
Keywords: trabeculectomy; mitomycin-C;
Ologen; adjuvants in trabeculectomy
Introduction
Many adjunctive modifications, such as
antimetabolites, amniotic membrane
transplantation, and expanded
polytetrafluoroethylene (Gore-Tex) implants,
have been tried in order to enhance and
maintain the hypotensive effect of
trabeculectomy.1–10
In various studies, adjunctive mitomycin-C
(MMC) has been demonstrated to increase the
success rate of trabeculectomy when compared
with trabeculectomy alone or with
postoperative 5-fluorouracil injections.1,2,11–13
Unfortunately, antimetabolite-augmented
glaucoma surgery can be associated with a
higher frequency of prolonged wound leaks,
hypotony with choroidal effusions and
maculopathy, thin avascular blebs, and/or bleb
leaks with late infection.9,14,15
Recently, a new biodegradable porous
collagen-glycosaminoglycan (GAG) copolymer
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matrix implant has been proposed for glaucoma surgery
on the basis of animal experiments.16–18 Ologen (OLO)
collagen matrix (Aeon Astron Europe BV, Leiden,
The Netherlands) is a biodegradable collagen-GAG
implant, available in various shapes and dimensions,
that may maintain the hypotensive effect in glaucoma
surgery and enhance the healing in other selected
ophthalmic surgeries (eg, pterygium or strabismus).
According to the manufacturer, when the OLO is directly
placed over the scleral flap, its porous structure should
force conjunctival fibroblasts and myofibroblasts to grow
into the pores and secrete connective tissue in the form of
a loose matrix, reducing scar formation and wound
contraction. After the implantation, the device should
completely degrade within 90–180 days.
A prospective, interventional case series with OLO
implantation for open-angle glaucoma demonstrated that
lower IOP correlates with bleb height, thin bleb wall,
large subconjunctival fluid spaces, and low bleb tissue
reflectivity.19 A prospective, randomized, medium-term
pilot study failed to show any IOP-lowering advantage
of the OLO and indicated a tendency to a higher
incidence of complications with the collagen implant.20
Recent data from a randomized study of trabeculectomy
using MMC vs an OLO implant showed a lower
complete success rate but a lower bleb-associated
complication rate in OLO group.21
The purpose of this randomized, prospective clinical
trial was to compare the outcomes of trabeculectomy
using either the adjunctive OLO implant or
intraoperative, low-dosage MMC. The parameters
measured included IOP, bleb morphology, and frequency
of complications.
Patients and methods
This study was a prospective randomized phase II
clinical trial undertaken in the Department of
Ophthalmology of Palermo University, Italy, between
January and December 2008. The protocol of this study
was approved by the Ethics Committee of University of
Palermo (Italy). Patients were thoroughly informed about
the procedures and written informed consent was
obtained in accord with tenets of Declaration of Helsinki.
Forty consecutive Caucasian glaucoma patients were
randomly assigned to undergo a trabeculectomy with
MMC (MMC group) or a trabeculectomy with OLO
implant (OLO group). Randomization was determined
just before surgery by sealed-envelope technique based
on their surgical chart number. The sequence of random
allocation was generated by pulling 40 standard sized
pieces of paper out of a hat by the trial statistician (AC).
Twenty pieces of paper were marked with letter A,
and 20 with letter B. Each piece of paper was sequentially
placed into 40 sealed, opaque envelopes by the trial
statistician. The sealed envelopes were numbered 1 to 40
and given to the surgeon (SC). Patients were numbered
randomly from 1 to 40 based on a surgical chart number
related to the baseline testing session and intervention
period. The clinical data collecting and measurement of
outcome variables were performed by skilled personnel
(ophthalmologists and optometrists) masked to
randomization and who had not been directly involved
in patient surgery.
Inclusion criteria were age 18 or older, diagnosis of
POAG or pseudoexfoliative glaucoma (PEXG), and
inadequate IOP control (IOP421 mm Hg) or progressive
visual field deterioration on maximum-tolerated
medical therapy. Exclusion criteria were normal-tension
glaucoma, use of systemic or ocular medications
that might affect vision, acute or chronic disease
that could confound the outcomes of the study
(eg, immunodeficiency, connective tissue disease, and
diabetes), clinically significant cataract where combined
surgery was indicated, and history of ocular trauma or
prior ocular surgery.
The preoperative data collected were age; gender;
medical history, including the presence of any ocular
pathology; number of antiglaucomatous drugs used;
applanation tonometry under maximum-tolerated
topical therapy; biomicroscopy; and computerized
Humphrey visual field testing (mean deviation and
pattern standard deviation).
IOP was the primary outcome measure and three
different IOP target levels were considered: r21, r17,
and r15 mm Hg. Complete success was defined as a
target end point IOP without antiglaucomatous
medications, while qualified success was defined as a
target end point IOP regardless of medications.
Secondary outcome measures included bleb
evaluation, according to Moorfields Bleb Grading
System (MBGS), which describes area, height, and
vascularity of bleb; number of glaucoma medications;
and frequency of postoperative adjunctive procedures
and complications.
Surgical techniques
Patients underwent surgery on the second day of
hospitalization. All operations were carried out under
local peribulbar anesthesia by one experienced surgeon
(SC). The technique included grasping the superior
rectus muscle with a 4-0 silk traction suture and creating
a superior fornix-based conjunctival/tenons flap with a
9-mm limbal conjunctival incision using Westcott
scissors. A rectangular 3.0 3.5 mm2-wide, 300-m thick
scleral flap was dissected at the 12-o’clock position using
a bevel-up crescent knife (Alcon, Milan, Italy). The scleral
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flap 3.0 mm side incisions were not completed up to
limbus. This should encourage greater posterior aqueous
flow and a more diffuse bleb, according to the
‘Moorfields Safer Surgery System’.22,23
When MMC was the randomized adjunctive therapy
(Kyowa S.r.l., Milan, Italy), a Weck-cell sponge was cut
into two to three pieces, B4 mm 2 mm 0.5 mm,
soaked with MMC at a concentration of 0.2 mg/ml and
placed under the dissected conjunctiva surrounding the
scleral flap22,23 and on the scleral bed.24 The sponges
were left in position for 2 min in order to maintain
contact with the Tenon’s capsule side of conjunctiva.
Thereafter, the eye was irrigated with 15 ml of balanced
salt solution. An ophthalmic viscoelastic (IAL-F, Bausch e
Lomb IOM SpA, Milan, Italy) was injected to increase the
iris–cornea depth and anterior chamber was entered at
the base of scleral flap with a 3.2 precalibrated knife
(Alcon Italia SpA). Two semicircular excisions 1.5 mm in
diameter were created with a Crozafon-De Laage punch
along the same radial line, in order to obtain an excision
of corneoscleral tissue including the trabecular
meshwork. A peripheral iridectomy was then performed,
followed by reinjection of viscoelastic into the anterior
chamber. The scleral flap was closed with two 10-0 nylon
sutures, one at each corner, applying minimal tension in
MMC cases and with one loose stitch in OLO cases. For
the OLO cases, a cylindrical 2.0±0.3 mm in
height 6.0±0.5 mm in diameter implant (model
number 830601, Aeon Astron Europe BV) was then
centered on the top of scleral flap and under the
conjunctiva. The conjunctival flap was secured to the
limbus with two 10-0 nylon single-stitch tensioning
sutures at the extremities of the limbal incision plus a
tight 10-0 nylon running suture with buried knots. The
filtration was assessed by injecting balanced salt solution
into the paracentesis. Postoperatively, all eyes were
treated with topical tobramycin 0.3% five times daily
until day 14, and with topical dexamethasone drops 0.1%
five times daily for 7 days, three times daily for 6 weeks
and twice a day for a final 1 week. If corkscrew bleb
vessels were present, more frequent topical steroid
administration was allowed, according to the ‘intensified
postoperative care’ (IPC) protocol.25 Instillation of 1%
atropine drops was added during the first few days, and
continued up to 1 week in cases with hypotony. If
needed, adjunctive procedures such as the Carlo
Traverso maneuver26 (ie, applying a pressure with a
cotton swab just temporal to the temporal radial groove
of the sclerostomy, to disrupt the incision during the time
of healing to try to prevent the sclerostomy from closing),
laser suture lysis or bleb needling (without
antimetabolites) were employed. If postoperative IOP
measurements were 421 mm Hg after topical steroid
withdrawal, IOP-lowering medication was added.
Postoperative visits were scheduled at 24±4 h, 7±1
days, 2 weeks, and 1, 2, 3, 6, 12, 18, and 24 months.
IOP (average of two separate readings), biomicroscopic
findings, number of antiglaucomatous medications, and
postoperative complications were assessed at each visit.
Signs of inflammation, such as cells and flare, were
graded from 0 to 4, as were any bleb complications, such
as cystic or avascular blebs.
At each follow-up visit, bleb photographs were
recorded and graded according to the MBGS27 by a single
observer (GC). Spectral domain optical coherence
tomography (SD-OCT; Topcon 3DOCT-1000, Topcon
Corporation, Tokyo, Japan) was performed at the end
point for bleb evaluation by one ophthalmologist (FDP)
masked to clinical data.
SD-OCT bleb analysis standardization was performed
as follows. The blebs were classified as successful when
the bleb wall was thickened (subjectively assessed
relative to conjunctival-episcleral appearance) and
discrete hyporeflective spaces or microcysts were
visualized in the bleb wall. The presence or absence of
bleb wall thickening and of the abovesaid intrableb wall
structures, which identified a bleb as successful or failed,
was assessed with respect to a r17 mm Hg target IOP
level.28,29 Thereafter, the sensitivity and specificity rates
were calculated.
Statistical analysis
The sample size of 40 patients (20 eyes in each group)
was chosen to achieve a power of 90% for detecting a
3 mm Hg difference in IOP between treatment
procedures, assuming a standard deviation of 3 mm Hg
and a two-sided a error of 5%.
The independent Student’s t-test and the Mann–
Whitney U statistic test were used for parametric and
non-parametric analysis, respectively. Discrete variables
were analyzed using the w2 and Fisher’s exact test, as
needed. The paired-samples Student’s t-test and paired
Wilcoxon signed-rank test were used for intragroup
parametric and non-parametric analysis, respectively. All
statistical tests were two-tailed and were applied at the
5% significance level. Success was evaluated on the basis
of Kaplan–Meier cumulative probability (log-rank test).
Before the study onset, we established an internal
quality control system to assess intraobserver
reproducibility and consistency by using three
consecutive independent interpretations of the same
SD-OCT scan, and by the use of the unweighted Cohen
kappa (k) test.30
Data were analyzed with Epi Info software, version
3.2.2 (Centers for Disease Control and Prevention,
Atlanta, GA, USA) and SPSS software (version 14.0; SPSS
Inc., Chicago, IL, USA).
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Results
All patients completed the 24-month follow-up period.
Patients in the two treatment groups did not significantly
differ in age, gender, type of glaucoma, mean
preoperative values of visual field parameters, and mean
number or duration of preoperative topical
antiglaucomatous medication and preoperative IOP
(Table 1).
The mean preoperative IOP (±SD) was 26.5 (±5.2)
in MMC eyes and 27.3 (±6.0) in OLO eyes,
without significant intergroup difference. One-day
postoperatively, the IOP dropped to 5.2 (±3.5) and 9.2
(±5.5) mm Hg, respectively (P¼ 0.009). No intergroup
difference was present at any scheduled postoperative
observation time. The postoperative IOP reduction was
still significant at the end point in all groups (P¼ 0.01),
with a mean IOP of 16.0 (±2.9) and 16.5 (±2.1) mm Hg
in MMC and OLO eyes, respectively. The percentage IOP
reduction from baseline was 39.6 and 39.5, respectively
(Table 2; Figure 1).
The success rates in the study groups are reported in
Table 3. Atr21 mm Hg target IOP, complete success was
achieved in 14 eyes (70%) and 15 eyes (75%) in MMC and
OLO groups, respectively, without significant intergroup
difference. At the same target IOP, a qualified success
was achieved in 17 (85%) and 18 (90%) eyes, respectively,
again without significant intergroup difference. A
r17 mm Hg target IOP complete success was obtained in
12 (60%) and 11 (55%) eyes in MMC and OLO groups,
respectively, while a qualified success was reached by 15
eyes (75%) in both groups. Finally, at r15 mm Hg target
IOP, 8 eyes (40%) and 10 eyes (50%) in MMC and OLO
groups reached a complete success, while 12 (60%) and
14 (70%) eyes reached a qualified success, respectively,
again without significant difference.
The Kaplan–Meier cumulative survival curves relating
either the r21, r17, or r15 mm Hg target IOP did not
show significant intergroup differences for complete
(log-rank P¼ 0.595, 0.999, and 0.349, respectively) or
qualified success rates (log-rank P¼ 0.131, 0.794, and
0.059, respectively) (Figure 2).
In order to allow for bleb stabilization, we performed
MBGS scores comparison between the groups at 3
months, 6 months, 1 and 2 years. The central area,
maximal area, and height score values (mean±SD) did
not differ on an intragroup basis over time, maintaining a
stable value till the end point in both surgical groups.
The end point mean score values relating central area,
maximal area, and height in MMC vs OLO group were
2.8±1.0 vs 2.7±1.0, 3.0±1.2 vs 2.9±1.0, and 1.3±0.7 vs
1.6±0.8, respectively. The same values, except for height,
did not differ between the two groups at any time. In
fact, the mean bleb height score was higher in OLO
group at the third month (2.0±0.8 vs 1.3±0.7; P¼ 0.009;
Mann–Whitney U statistic test), maintaining a higher yet
not significant value till the end point. The mean
vascularity scores did not differ on an intragroup and
intergroup basis over time. The end point central,
peripheral, and non-bleb vascularity mean score values
in MMC vs OLO group were 2.0±1.0 vs 2.1±1.0, 2.0±1.2
vs 2.0±1.0, and 2.0±1.0 vs 2.0±1.0, respectively. No
cases with subconjunctival blood were recorded.
Table 1 Preoperative characteristics of patients
MMC group OLO group P
Gender (M/F), N1 11/9 12/8 1.0a
Age, years (mean±SD) 63.2 (7.2) 65.8 (6.4) 0.234b
Right/left eyes, N1 7/13 11/9 0.340a
Type of glaucoma (POAG/PEXG), N1 12/8 13/7 1.0a
Preoperative IOP, mm Hg (mean±SD) 26.5 (5.2) 27.3 (6.0) 0.654b
Mean deviation, dB (mean±SD) 7.80 (4.57) 7.41 (5.35) 0.805b
Pattern standard deviation, dB (mean±SD) 7.20 (4.10) 7.0 (4.23) 0.880b
Preoperative medications, N1 (mean±SD) 2.5 (0.3) 2.6 (0.2) 0.222b
Duration of preoperative antiglaucoma therapy, years (mean±SD) 5.7 (1.8) 6.3 (1.4) 0.246b
Abbreviations: MMC, mitomycin-C; OLO, Ologen; POAG, primary open angle glaucoma; PEXG, pseudoexfoliation glaucoma.
aw2-test or Fisher’s exact test, as needed.
bIndependent Student’s t-test.
Table 2 Postoperative IOP (mm Hg) in the surgical groups
from the 3rd month till end point
MMC group OLO group Pa
3rd month 14.7 (3.9; 12.9–16.4) 15.0 (3.8; 13.3–16.7) 0.806
44.5% 45.1%
6th month 14.7 (4.3; 12.7–16.6) 14.1 (3.1; 12.6–15.4) 0.615
44.5% 48.4%
12th month 15.0 (3.0; 13.6–16.4) 15.2 (2.8; 13.8–16.4) 0.828
43.4% 44.3%
24th month 16.0 (2.9; 14.6–17.4) 16.5 (2.1; 15.5–17.4) 0.536
39.6% 39.5%
Abbreviations: MMC, mitomycin-C; OLO, Ologen.
aIndependent Student’s t-test.
Mean (±SD; 95% CI); % change in IOP from baseline.
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There was high intraobserver reproducibility for
SD-OCT analysis (k¼ 0.7403, 95% CI: 0.70–0.86). Table 4
shows the SD-OCT frequencies of thickened bleb wall
and visualized discrete hyporeflective spaces (or
microcysts), which identified a bleb as successful
(Figure 3, top left and right), with respect to a
r17 mm Hg target IOP level at 2-year follow-up. A
successful bleb was exhibited in 10 of 12 eyes with
complete success based on IOP in the MMC group
(Figure 3, top left), and in 8 of 11 in the OLO group
(Figure 3, top right). These values represent a sensitivity
of 83% and 73%, respectively. Conversely, when
considering the eyes without complete success, an
SD-OCT-failed bleb (Figure 3, bottom left and right)
was present in 6 of 8 MMC (Figure 3, bottom left) and
6 of 9 OLO (Figure 3, bottom right) eyesFa specificity of
75% and 67%, respectively.
The mean number of antiglaucoma medications was
significantly reduced at the end point in both groups
(P¼ 0.0001): from 2.5 (±0.3) to 0.8 (±0.2) and from 2.6
(±0.2) to 0.9 (±0.2) in the MMC and OLO groups,
respectively, without significant intergroup differences
(P¼ 0.122).
Two patients in each group underwent the Carlo
Traverso maneuver between the 1st and the 14th
postoperative day. Laser suture lysis was performed
between the first and the second postoperative week in
four cases (20%) in the MMC group and in three cases
(15%) in the OLO group, without intergroup difference.
Bleb needling for encapsulated blebs was performed
Table 3 Success rates (%) at the 24-month follow-up study end
point in the surgical groups at three target IOP levels
MMC group OLO group Pa
r21mmHg
Complete success 14 (70%) 15 (75%) 1.0
Qualified success 17 (85%) 18 (90%) 1.0
r17mmHg
Complete success 12 (60%) 11 (55%) 1.0
Qualified success 15 (75%) 15 (75%) 1.0
r15mmHg
Complete success 8 (40%) 10 (50%) 0.751
Qualified success 12 (60%) 14 (70%) 0.741
Abbreviations: MMC, mitomycin-C; OLO, Ologen.
aFisher’s exact test.
Figure 2 Kaplan–Meier cumulative probability curve of com-
plete success (without medications) atr15 mm Hg target IOP in
MMC (solid line) vs OLO group (dotted line) (log-rank test
P¼ 0.349).
Figure 1 Box-plot representation of IOP values over 24 months
of follow-up: median values (dark lines), error standard (T-bars),
and outliers (circles). Table 4 Bleb success rates (%) atr17 mm Hg target IOP in the
surgical groups according to the SD-OCT analysis
MMC
group
OLO
group
P
Successful bleb/eyes with
complete success
10/12 8/11 0.640a
Failed bleb/eyes without
complete success
6/8 6/9 1.0a
SD-OCT sensitivity 83% 73% 0.871b
SD-OCT specificity 75% 67% 0.767b
Abbreviations: MMC, mitomycin-C; OLO, Ologen.
aFisher’s exact test.
bw2-test for the comparison of two proportions (from independent
samples), expressed as a percentage.
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from one to four times in seven (35%) and six (30%)
patients, respectively, again without intergroup
difference.
The anterior chamber cells score was higher in OLO
than in MMC group in the first postoperative day
(2.4±0.8 vs 1.8±0.6, respectively, P¼ 0.018), while the
mean flare score was higher in MMC than in OLO group
during the second postoperative week (0.3±0.7 vs 0,
respectively, P¼ 0.038).
The frequency of postoperative complication did not
significantly differ between the two groups (Table 5).
Early bleb leakage was more frequent in the OLO than in
the MMC group (3 vs 1 eye, respectively, P¼ 0.604), while
early hypotony was more frequent in MMC than in OLO
group (8 vs 4 cases, respectively, P¼ 0.300), with an
increased frequency of choroidal detachment in the
former (5 vs 2 cases, respectively, P¼ 0.407). Two cases
with not clinically significant avascular bleb (3a-1
according to MBGS) were noted in MMC group. No
adverse reaction to the OLO, matrix extrusion, or
conjunctival erosion was noted in OLO group.
Discussion
The need for alternative adjuvants to antimetabolites in
glaucoma surgery arises from the difficult balance
between loss of efficacy and postoperative complications
related to hypotony. Early complications are mainly
related to the procedure (eg, flaps fashioning, suturing
technique, etc.), while late complications are caused by
the prolonged fibroblast inhibition, with thin avascular
blebs that are prone to leak. In our study, we applied
one loose stitch in the OLO cases in order to
counterbalance the pressure of the cylindrical implant
over the scleral flap. This pressure could be indirectly
confirmed by the first postoperative day’s reduced
tendency to hypotony in the OLO cases as compared
with the MMC ones. OLO could therefore induce a
modulation of the aqueous outflow occupying the
subconjunctival space by its volume and applying a
pressure on the top of the scleral flap.
There was no significant difference in the
postoperative behavior between the two groups, with a
highly significant and stable IOP reduction and very few
antiglaucoma medications throughout the 24-month
follow-up, indicating that the efficacy of the OLO
Figure 3 SD-OCT imaging of blebs postoperatively in eyes with or without complete success based on r17 mm Hg target IOP.
Successful (‘thickened’) blebs in eye with complete success (MMC adjuvant, top left; OLO adjuvant, top right). Failed (‘non-thickened’)
blebs without complete success (MMC adjuvant, bottom left; OLO adjuvant, bottom right).
Table 5 Frequency (%) of postoperative complications in the
surgical groups
MMC group OLO group Pa
Early hyphema 1 (5%) 1 (5%) 1.0
Early bleb leakage 1 (5%) 3 (15%) 0.604
Early hypotony 8 (40%) 4 (20%) 0.300
Choroidal detachment 5 (25%) 2 (10%) 0.407
Abbreviations: MMC, mitomycin-C; OLO, Ologen.
aFisher’s exact test.
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implant is analogous to MMC. The similarity between
OLO and MMC is further confirmed by their success
rates at each target IOP level we considered.
The higher bleb height score in OLO group at the 3rd
month could testify the persistence of the implant, whose
volume could be added to the fluid-filled bleb spaces,
and whose biodegradation, according to the
manufacturer, can last a 6-month period. It is possible
that a larger sample could have confirmed this difference
in height for a longer period.
These data appear to be in contrast with the results of a
recent paper where the bleb height at 60 days was lower
and the vascularity bleb was higher in OLO group, where
a lower success rate was noted when compared with
MMC-treated eyes.31 This finding is discussed below.
In studies using either morphologic grading scale
evaluation or experimental 3D anterior segment SD-OCT,
bleb height is one of the parameters correlated with a
lower IOP.28,32–34 While we observed a better bleb height
persistence at one time in OLO group, we failed to
demonstrate a better success rate. It is possible that the
difference in bleb morphologic features was not large
enough to significantly affect IOP control in the defined
follow-up period.
The SD-OCT examination failed to show any
qualitative difference in outer bleb appearance between
the groups, indicating that the OLO implant neither
enhances nor modifies the morphology of the outer
layers of a functioning bleb. A larger sample size could
confirm if the SD-OCT pattern of a successful bleb,
besides confirming good test sensitivity, represents a
prognostic factor for longer-term success.
The similar frequency of adjunctive postoperative
procedures confirms the analogous performance of the
intraoperative adjuvants.
The early, yet not significant, bleb leakage in OLO eyes
can be ascribed to conjunctival flap limbal elevation
induced by the implant volume, indicating a transitory
mechanical effect.
The similar rates of postoperative complications in the
two groups failed to reveal differences between the two
adjuvants. The absence of cystic blebs and of the typical
‘ring of steel’ in both groups is partly due to the lack of
significant reaction to the OLO insert with our
therapeutic regimen and to the diffuse application and
low dosage of MMC. The low complication rate with
low-dosage MMC in our sample is in agreement with our
previous studies.8,24,35,36
A recent pilot study20 is not in agreement with our
results, since it showed OLO to have a larger amount of
complications than simple trabeculectomy. The
conjunctival closure with two simple 10-0 nylon sutures
at the flap extremities was probably responsible for a
higher incidence of positive Seidel test with flat anterior
chamber in the study group, and could have reduced the
beneficial effect of the implant in bleb development.
Moreover, the reduced time of steroid administration,
1 month vs 2 months with variable regimen based on
IPC criteria in our study, could have affected the
vascularity control in OLO eyes, resulting in a
hypothetical excess of fibroblast proliferation around and
into the implant and higher end point IOP. The lower
success rate and bleb functionality in OLO cases when
compared with MMC ones, with a higher complication
rate in the latter, reported in two studies,21,31 could
hypothetically be ascribed to various factors such as
small sample size, OLO size and manufacturer,
concentration and modality of application of MMC, or
postoperative therapeutic regimen.
Major limitations of our study consist, besides the
small sample size, in the inclusion of PEXG, which is a
‘secondary’ glaucoma. On the other side, in our country
the presence of PEXG is common (430%), and our
sample adequately represents its prevalence in the
general population.
In conclusion, our results suggest that the OLO
implant could be a new, safe, and effective alternative to
MMC, with similar long-term success rate. The OLO
implant may for instance be preferred when
antimetabolite-related risks need to be avoided and may
be useful in situations where IOP lowering and
maximum safety are required, such as in high hyperopia,
hemorrhagic risk, and monocularity. Due to our
relatively small sample size, which limits the statistical
comparison between the groups, further larger
randomized trials are required to investigate the long-
term efficacy and safety of this new device.
Summary
What was known before
K Trabeculectomy, introduced in 1968, remains the gold
standard in the majority of eyes requiring glaucoma
surgery.
K However, progressive loss of efficacy in some eyes
remains an unsolved problem with this procedure.
K Many adjunctive modifications, such as antimetabolites or
amniotic membrane transplantation have been tried in
order to enhance and maintain the hypotensive effect of
trabeculectomy.
What this study adds
K Our results suggest that the Ologen biodegradable
collagen matrix implant could be useful as an adjuvant in
trabeculectomy, and it is a new, safe, and effective
alternative to MMC, with similar long-term success rate.
K The Ologen implant may for instance be preferred when
antimetabolite-related risks need to be avoided and may
be useful in situations where IOP lowering and maximum
safety are required, such as in high hyperopia,
hemorrhagic risk, and monocularity.
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